Hippocratic AI Launches Japanese-Language healthcare agent
TOKYO — May 3, 2024 — Hippocratic AI, in collaboration with EUCALIA, is launching a Japanese-language healthcare agent. This innovative generative AI agent will handle non-diagnostic,patient-facing tasks,including appointment scheduling so clinicians can focus on patient care. This strategic move by Hippocratic AI is designed to alleviate the stresses on Japan’s healthcare system,ensuring more effective patient outcomes.
Hippocratic AI Partners with EUCALIA to Launch Japanese-Language Healthcare Agent
Hippocratic AI, a generative artificial intelligence company focused on developing safe large language models for healthcare, is expanding its reach into Japan. The company has announced a partnership with EUCALIA, a healthcare transformation firm, to introduce the first Japanese-language generative AI healthcare agent designed for non-diagnostic, patient-facing clinical tasks.
Entering the Japanese Market
This collaboration marks a significant milestone for Hippocratic AI, signaling its entry into the Japanese healthcare market. EUCALIA, known for providing management and operational support to healthcare professionals, will play a crucial role in deploying and integrating the new AI agent.
Did you know?
JapanS healthcare system is renowned for its high standards and universal coverage. However, it faces challenges related to an aging population and increasing demand for services.
AI Agent Capabilities
The japanese generative AI healthcare agent, slated for introduction this year, is designed to assist clinicians by handling time-consuming, yet essential, non-diagnostic tasks. Thes tasks include:
- Appointment scheduling
- Follow-up outreach
- Chronic care check-ins
- Medication adherence support
Hippocratic AI aims to enhance clinician workflow efficiency, improve patient engagement, and ultimately, drive better patient outcomes.
This partnership with EUCALIA reflects our commitment to building generative AI agents that are not just multilingual but locally fluent,clinically safe and culturally aligned.
Munjal Shah,CEO and cofounder of Hippocratic AI
Addressing Healthcare Strain in Japan
Shah further emphasized the potential impact of the technology on Japan’s healthcare system:
Japan’s healthcare system is world-class but under strain,and we believe our technology can meaningfully extend its capacity without compromising quality or trust. Together with EUCALIA, we are setting a new global benchmark for how generative AI can responsibly improve patient outcomes, enhance clinical operations at scale and support a more resilient healthcare system for the people of Japan.
Munjal Shah, CEO and cofounder of Hippocratic AI
Pro Tip
generative AI in healthcare can substantially reduce administrative burdens, allowing healthcare professionals to focus more on direct patient care.
Recent Developments at Hippocratic AI
Hippocratic AI has been actively expanding its partnerships and team. In April, the company announced a strategic alliance with Burjeel Holdings, a healthcare services provider based in the United Arab Emirates, to transform healthcare delivery. This partnership involves deploying Hippocratic AI’s generative AI healthcare agents across Burjeel Holdings’ facilities in the UAE and Oman.
The integration of Hippocratic AI’s technology has enabled Burjeel Holdings to enhance patient engagement and provide personalized clinical conversations.
In March, hippocratic AI appointed seven new executives following a $141 million Series B funding round in January. These executives include:
- Dr.Chris Fang, chief commercial officer for pharma, life sciences and international markets
- Hollie Vugrinovich, chief growth officer for providers
- W.B. “Mitch” Mitchell, chief growth officer for the government sector
- Chitra Laxmanan, vice president and general manager for payors
- Eric Seastedt, vice president for international emerging markets
Series B funding
In January, Hippocratic AI closed a $141 million Series B round, bringing its valuation to $1.64 billion. The funding round was led by Kleiner Perkins, with participation from existing investors such as SV Angel, Premji, General Catalyst, A16Z, NVIDIA, Universal Health Services, and WellSpan Health.
